Hostname: page-component-8448b6f56d-jr42d Total loading time: 0 Render date: 2024-04-18T02:22:34.742Z Has data issue: false hasContentIssue false
  • English
  • Français

The Switching of Risperidone to Olanzapine in Elderly Nursing-Home Patients with Dementia: A Retrospective Study

Published online by Cambridge University Press:  07 November 2014

Subramoniam Madhusoodanan  and
Olivera Bogunovic
Get access Rights & Permissions [Opens in a new window]

Abstract

Background:

The behavioral and psychological symptoms of dementia present a major challenge in the management of these patients. There is no Food and Drug Administration-indicated medication for the management of these symptoms. Even though atypical antipsychotics are considered safer than conventional antipsychotics, safety concerns have emerged.

Introduction:

The FDA has issued warnings regarding the cardiac and metabolic side effects, cerebrovascular events, and, most recently, mortality risk. This study was conducted in 2003 when physicians were notified of the cerebrovascular risks of risperidone. Since then, similar warnings have been issued for olanzapine and aripiprazole.

Methods:

The medical records of 58 elderly dementia patients who were taking risperidone and were abruptly switched to olanzapine were reviewed. Clinical Global Impressions scale at assigned retrospectively at switch, and weeks 4–6 assessed treatment.

Results:

Baseline and follow-up Clinical Global Impressions scale scores were essentially unchanged. Adverse events were mild to moderate in severity. Mean risperidone dose at switch was 1.54 mg/day (range: 0.25–6 mg/day). Mean olanzapine dose after the switch was 5.69 mg/day (range: 2.52–27.5 mg/day).

Conclusion:

Most of the 58 patients were switched from risperidone to olanzapine without any deterioration in their clinical status. Even though it is generally not recommended in elderly patients, abrupt switching did not have any negative consequences in this group of patients.

Type
Original Research
Information
CNS Spectrums , Volume 12 , Issue 1 , January 2007 , pp. 46 - 50
Copyright
Copyright © Cambridge University Press 2007

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1.Madhusoodanan, S. Introduction: antipsychotic treatment of behavioral and psychological symptoms of dementia in geropsychiatric patients. Am J Geriatr Psychiatry. 2001;9:283–288.CrossRefGoogle ScholarPubMed
2.Jeste, DV, Finkel, SI. Psychosis of Alzheimer's disease and related dementias. Diagnostic criteria for a distinct syndrome. Am J Geriatr Psychiatry. 2000;8:29–34.CrossRefGoogle ScholarPubMed
3.Katz, IR, Jeste, DV, Mintzer, JE, Clyde, C, Napolitano, J, Brecher, M. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized double blind trial. Risperidone Study Group. J Clin Psychiatry. 1999;60:107–115.CrossRefGoogle ScholarPubMed
4.Street, JS, Clark, WS, Gannon, KS, et al. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer's disease in nursing care facilities: A double-blind, randomized placebo-controlled trial. The HGEH Study Group. Arch Gen Psychiatry. 2000;57:968–976.CrossRefGoogle Scholar
5.Zhong, K, Tariot, P, Mirkwitz, MD, et al. Quetiapne for the treatment of agitation in elderly institutionalized patients with dementia: a randomized double-blind trial. Poster presented at: 9th International Conference on Alzheimer's Disease and Related Disorders. July 17-22, 2004; Philadelphia, Penn.Google Scholar
6.Cole, S, Sablosky, M, Smith, A, et al. Ziprasidone for agitation or psychosis of dementia. Poster presented at: Annual Meeting of the American Association for Geriatric Psychiatry. March 3-6, 2005; San Diego, Calif.Google Scholar
7.Streim, JE, McQuade, RD, Stock, E, et al. Aripiprazole treatment of institutionalized patients with psychosis of Alzheimer's dementia. Poster presented at: Annual Meeting of the American Association of Geriatric Psychiatry. Feb 21-24, 2004; Baltimore, MD.Google Scholar
8.Laughren, T. A regulatory perspective on psychiatric syndromes in Alzheimer's disease. Am J Geriatr Psychiatry. 2001;9:340–345.CrossRefGoogle Scholar
9.Wooltraton, W. Risperidone (Risperdal): increased rate of cerebrovascular events in dementia trials. CMAJ. 2002;167:1269–1270.Google Scholar
10.Schneider, L. Mortality in dementia trials: pooled analysis. Poster presented at: 9th International Conference on Alzheimer's Disease. July 17-22, 2004; Philadelphia, Penn.Google Scholar
11.American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs, and obesity and diabetes. Diabetes Care. 2004;27:596–601.CrossRefGoogle Scholar
12.Guy, W, ed. ECDEU Assessment Manual for Psychopharmacology. Washington, DC: US Department of Health, Education, and Welfare. Publication ADM 76-338; 1976.Google Scholar
13.Winans, EA. Switching antipsychotics: a balanced approach to ease the transition. Current Psychiatry. 2003;2:53–64.Google Scholar
14.Madhusoodanan, S, Suresh, P, Brenner, R, Pillai, R. Experience with atypical antipsychotics–risperidone and olanzapine in the elderly. Ann Clin Psychiatry. 1999;11:113–118.CrossRefGoogle ScholarPubMed
15.Barak, Y, Shamir, E, Mirecki, I, Weizman, R, Aizenberg, D. Switching elderly chronic psychotic patients to olanzapine. Int J Neuropsychopharmacol. 2004;7:165–169.CrossRefGoogle ScholarPubMed
16.Madhusoodanan, S, Brenner, R, Suresh, P, et al. Efficacy and tolerability of olanzapine in elderly patients with psychotic disorders: a prospective study. Ann Clin Psychiatry. 2000;12:11–18.CrossRefGoogle ScholarPubMed
17.Madhusoodanan, S, Sinha, S, Brenner, R, Gupta, S, Bogunovic, O. Use of olanzapine for elderly patients with psychotic disorders: a review. Ann Clin Psychiatry. 2001;13:201–213.CrossRefGoogle ScholarPubMed
18.Jeste, DV, Barak, Y, Madhusoodanan, S, Grossman, F, Gharabawi, G. International multisite double-blind trial of the atypical antipsychotics risperidone and olanzapine in 175 elderly patients with chronic schizophrenia. Am J Geriatr Psychiatry. 2003;11:6;638–647.CrossRefGoogle ScholarPubMed
19.Fontaine, CS, Hynan, LS, Koch, K, Martin-Cook, K, Svetlik, D, Weiner, MF. A double-blind comparison of olanzapine versus risperidone in the acute treatment of dementia-related behavioral disturbances in extended care facilities. J Clin Psychiatry. 2003;64:726–730.CrossRefGoogle ScholarPubMed
20.Deberdt, WG, Dysken, MW, Rappaport, SA, et al. Comparison of olanzapine and risperidone in the treatment of psychosis and associated behavioral disturbances in patients with dementia. Am J Geriatr Psychiatry. 2005;13:722–730.CrossRefGoogle ScholarPubMed
21.Sink, KM, Holden, KF, Yaffe, K. Pharmacological treatment of neuropsychiatric symptoms of dementia. a review of the evidence. JAMA. 2005;293:596–608.CrossRefGoogle ScholarPubMed
22.Schneider, LS, Dagerman, KS, Insel, P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA. 2005;294:1934–1943.CrossRefGoogle ScholarPubMed
23. Food and Drug Administration Web site. FDA Public Health Advisory: deaths with antipsychotics in elderly patients with behavior disturbances. Available at: http://www.fda.gov/eder/drug/advisory/antipsychotics.htm. Accessed April 13, 2005.Google Scholar
24.Wang, PS, Schneeweiss, S, Avorn, J, et al. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med. 2005;353:2335–2341.CrossRefGoogle ScholarPubMed